San Antonio Breast Cancer Symposium | Conference

Postoperative Radiotherapy Can Be Omitted Without Impacting Metastatic Risk in Low-Grade Breast Cancer

December 10th 2020

December 9, 2020 - Whole breast irradiation, following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

Dr. Kunkler on the 10-Year PRIME 2 Data Examining Post-Surgery Radiation in Breast Cancer

December 9th 2020

Ian Kunkler, FRCP, FRCR, DMRT, MRCP, discusses the 10-year results of the PRIME 2 trial in patients with breast cancer

Oral Paclitaxel/Encequidar Combo Improves Survival in Metastatic Breast Cancer

December 9th 2020

December 9, 2020 - The combination of oral paclitaxel and encequidar led to an estimated 26.5% reduction in the risk of death compared with intravenous paclitaxel in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.

Dr. Kalinsky on Initial Results of the RxPONDER Trial in HR+/HER2- Breast Cancer

December 9th 2020

Kevin Kalinsky, MD, MS, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor–positive, HER2-negative breast cancer.

AI-Digital Breast Cancer Risk Assessment Platform Accurately Classifies Low-Risk Recurrence Scores

December 9th 2020

December 9, 2020 - The artificial intelligence–digital breast cancer risk discrimination platform PreciseDx was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

Tumor Subtype Can Be a Prognostic Marker for Patients Treated with Ribociclib

December 9th 2020

December 9, 2020 - Intrinsic tumor subtype was found to be associated with prognosis in patients with hormone receptor–positive, HER2-negative advance breast cancer who received the CDK4/6 inhibitor ribociclib.

Women Who Undergo Mastectomy with Reconstruction At Higher Risk for Chronic Controlled Substance Use

December 9th 2020

December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.

Serial Circulating Tumor Cell Enumeration Predicts OS in Metastatic Breast Cancer

December 9th 2020

December 9, 2020 - Follow-up circulating tumor cell assessments were confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer, when performed at a median of 29 days following treatment initiation.

Symptoms Under-Recognized in Patients Who Receive Radiotherapy After Lumpectomy

December 9th 2020

December 8, 2020 - Oncologists widely under-recognize substantial symptoms in patients with breast cancer receiving radiotherapy after undergoing a lumpectomy, highlighting a need to improve symptom detection.

Menopausal Status May Inform Need for Chemotherapy in Lymph Node+, HR+/HER2- Breast Cancer

December 9th 2020

The addition of chemotherapy to endocrine therapy led to an improvement in 5-year invasive disease-free survival and overall survival in premenopausal but not postmenopausal women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

Abemaciclib Continues to Show Reduced Risk in iDFS in High-Risk Early HR+ Breast Cancer

December 9th 2020

December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer

January 14th 2020

Hope S. Rugo, MD, FASCO, discusses the updated findings of the SOPHIA trial in HER2-positive metastatic breast cancer.

Murthy Shares Insight on HER2CLIMB Findings With Tucatinib in HER2+ Breast Cancer

January 14th 2020

Rashmi K. Murthy, MD, MBE, discusses the findings of the HER2CLIMB trial in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Piccart Highlights 6-Year Follow-Up With Adjuvant Pertuzumab Regimen in HER2+ Breast Cancer

January 13th 2020

Martine J. Piccart, MD, PhD, discusses the 6-year follow-up of the APHINITY trial and its impact on the breast cancer field.

Real-World Abemaciclib Use in MBC Is Heterogeneous

January 3rd 2020

In the first 11 months following the FDA approval of the CDK4/6 inhibitor abemaciclib as a single agent and in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer, it is being used heterogeneously, including in patients with characteristics indicative of worse prognosis.

Absolute Lymphocyte Count May Predict Eribulin Benefit in Breast Cancer

December 28th 2019

A high absolute lymphocyte count at baseline appears to be an independent predictor for longer overall survival in patients with metastatic breast cancer who are treated with eribulin mesylate.

Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC

December 16th 2019

Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.

Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk

December 16th 2019

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer

December 14th 2019

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

Neoadjuvant Olaparib Combo Safe in Breast Cancer

December 14th 2019

Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline BRCA mutations.